HC Wainwright Comments on OTCMKTS:BPMUF FY2026 Earnings

Key Points

• HC Wainwright projects Basilea Pharmaceutica AG (OTCMKTS:BPMUF) will achieve earnings of $4.93 per share for FY2026, as detailed in a recent research report.
• The stock opened at $67.75 with a fifty-two week range between $47.50 and $67.75.
• Basilea Pharmaceutica specializes in developing biopharmaceutical products, particularly focusing on oncology and anti-infectives, with key offerings like the antifungal drug Cresemba.

Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Free Report) - HC Wainwright issued their FY2026 earnings per share estimates for Basilea Pharmaceutica in a research report issued on Monday, September 22nd. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of $4.93 per share for the year.

Basilea Pharmaceutica Stock Performance

Shares of Basilea Pharmaceutica stock opened at $67.75 on Thursday. Basilea Pharmaceutica has a fifty-two week low of $47.50 and a fifty-two week high of $67.75. The company has a quick ratio of 4.16, a current ratio of 4.85 and a debt-to-equity ratio of 1.18. The company has a fifty day moving average of $66.60 and a 200 day moving average of $57.70.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.